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Binding to helix 12 of the ligand-binding domain
of PPARg is required for full agonist activity.
Previously, the degree of stabilization of the ac-
tivation function 2 (AF-2) surface was thought
to correlate with the degree of agonism and
transactivation. To examine this mechanism,
we probed structural dynamics of PPARg with
agonists that induced graded transcriptional
responses. Here we present crystal structures
and amide H/D exchange (HDX) kinetics for
six of these complexes. Amide HDX revealed
each ligand induced unique changes to the dy-
namics of the ligand-binding domain (LBD). Full
agonists stabilized helix 12, whereas intermedi-
ate and partial agonists did not at all, and rather
differentially stabilizedother regionsof thebind-
ing pocket. The gradient of PPARg transactiva-
tion cannot be accounted for solely through
changes to the dynamics of AF-2. Thus, our
understanding of allosteric signaling must be
extended beyond the idea of a dynamic helix 12
acting as a molecular switch.
INTRODUCTION
Peroxisome proliferator-activated receptors (PPARs) be-
long to the nuclear receptor superfamily of transcription
factors, acting as obligate heterodimers with the retinoid
X receptor (RXRa, b, and g) to control genes implicated
in energy, carbohydrate, and lipid metabolism (Berger
and Wagner, 2002; Chawla et al., 2001). These heterodi-
meric transcriptional complexes can be activated by ago-
nists of either PPAR or RXR such as eicosanoids, prosta-
glandins, retinoic acids, and synthetic agonists, allowing
the integration of transcriptional responses from two dis-
tinct ligand-regulated signaling pathways (Forman et al.,
1995; Gottlicher et al., 1992; Kliewer et al., 1997, 1992).
One important class of synthetic agonist of peroxisome
proliferator-activated receptor gamma (PPARg) is the1258 Structure 15, 1258–1271, October 2007 ª2007 Elsevier Ltthiazolidinediones (TZDs) (e.g., rosiglitazone and pioglita-
zone) (Greene, 1999). TZDs are antidiabetic agents that
target adipose tissue and improve insulin sensitivity
through pleiotropic effects (Day, 1999; Pearson et al.,
1996). Despite the clinical benefit of these drugs, use of
TZDs has been associated with adverse effects including
weight gain, increased adipogenesis, renal fluid retention,
and plasma volume expansion and, more recently, possi-
ble increased incidence of cardiovascular events (Berger
et al., 2005; Nissen and Wolski, 2007). It is interesting to
note that the structurally similar PPARg TZD full agonists
rosiglitazone (Avandia) and pioglitazone (Actos) afford dif-
ferent clinical adverse events. This indicates that subtle
changes in ligand receptor interaction lead to differences
in the pharmacology of these agents, highlighting the im-
portance of the need for a more complete understanding
of the mechanism of ligand modulation of PPARg.
As a result of the clinical observations mentioned
above, emphasis has shifted to the development of
‘‘selective PPARg modulators’’ or SPPARMs. SPPARMs
are PPARg modulators that exhibit potent insulin sensiti-
zation activity but are antiadipogenic in animal models of
type 2 diabetes (Berger et al., 2003; Rangwala and Lazar,
2002; Rocchi et al., 2001). Partial agonists display re-
duced transcriptional activity in reporter assays and, in an-
imal models of type 2 diabetes, they demonstrate the
SPPARM phenotype.
Selective recruitment of transcriptional coactivators has
been implicated in partial agonist and SPPARM pheno-
type. The binding of agonist to the receptor’s LBD induces
structural changes that facilitate dissociation of repressor
molecules (e.g., NCoR and SMRT) and association of ac-
tivator proteins (Nagy et al., 1999; Shiau et al., 1998).
These transcriptional coactivators bind to the receptor
complex, modify local chromatin structure, and recruit
the transcription machinery to target gene promoters
(Rosenfeld et al., 2006). Partial agonists have been shown
to have decreased recruitment of CBP and SRC1 coacti-
vators (Fujimura et al., 2005) but retain association with
PGC1a (Burgermeister et al., 2006).
Significant effort has been placed on dissecting the
mechanism of ligand activation of PPARg. Based on pre-
vious studies, it has been suggested that communication
between ligand and coregulator binding sites occursd All rights reserved
Structure
Mechanism of Ligand Activation of PPARgthrough a molecular switch comprised of the most car-
boxy terminal helix, H12 of the LBD (Nagy and Schwabe,
2004; Rosenfeld et al., 2006). Full agonist ligands contact
PPARg H12, stabilizing the agonist conformation through
a direct hydrogen bond to Tyr473, allowing H12 to dock
against H3 and H11 (Nolte et al., 1998). In this conforma-
tion, H12 forms part of the coactivator-binding site (AF-2
surface), along with H3-5. Antagonists physically obstruct
the agonist conformation of H12 through a bulky pendant
group that protrudes from within the ligand-binding
pocket or, in the case of the antagonist GW-9662, which
covalently modifies Cys313 similar to the partial agonist
L-764406, blocks agonist binding (Bendixen et al., 2001;
Elbrecht et al., 1999; Shiau et al., 1998).
Previous X-ray crystallographic studies have revealed
that agonist-bound and apo PPARg LBDs are largely con-
served with no global differences. The large similarity of
apo, full-agonist-, and partial-agonist-bound structures
lead to the hypothesis that differences in ligand binding
modes were controlled largely by dynamics, particularly
H12 and the AF-2 surface. The structure of a partial-ago-
nist-bound PPARg showed no direct interactions between
ligand and H12 (Oberfield et al., 1999), supporting the idea
that this structural feature is key tomaximal transactivation
potency. This model is further supported by fluorescence
labeling of H12 (Kallenberger et al., 2003), which demon-
strated that full agonists stabilize PPARgH12. These stud-
ies implicated that the degree of H12 stabilization is pro-
portional to the degree of agonism and transcriptional
output for full agonists. However, these studies did not ex-
amine partial agonist interactions andwere designed such
that they could only examine the dynamics of H12.
Amide hydrogen/deuterium exchange (HDX) is an
established technique for measuring protein dynamics
(Englander, 2006; Maier and Deinzer, 2005; Shi et al.,
2006). In contrast to fluorescence labeling methods, no
prior modification of the protein of interest is required
and kinetic information may be obtained across the entire
protein. Previously, Yan and colleagues utilized HDX to
probe conformational dynamics of the retinoid X receptor
alpha LBD (RXRa LBD) in the presence and absence of 9-
cis-retinoic acid (9-cis-RA) (Yan et al., 2004). In that study,
perturbation in HDX kinetics of RXRa LBD upon 9-cis-RA
binding correlatedwell with changes in hydrogen bonding,
amino acid residue depth, and solvent exposure predicted
from the cocrystal structure. However, perturbation in ex-
change kinetics was also observed in regions not pre-
dicted from the X-ray structure. Yan’s work illustrates
the complementary relationship between HDX kinetics
and X-ray crystallography and demonstrates the ability
of HDX to detect allosteric effects on dynamics as a result
of ligand binding.
We recently presented the first HDX study of PPARg
bound to a molecule with a low transactivation potential
(partial agonist) and found no changes in the dynamics
of H12 as compared to the apo receptor (Hamuro et al.,
2006). Selective loss of coactivator recruitment with par-
tial agonists was hypothesized to derive from lack of sta-
bilization of the coactivator-binding site AF-2. This sup-Structure 15, 1258–12ports a model whereby stabilization of H12 correlates
with full transcriptional activity; however, the model could
not explain the transactivation activity of partial agonists
that do not stabilize H12 at all. More importantly, previous
studies cannot explain the activity of intermediate ago-
nists such as BVT.13, which affords transactivation poten-
tial twice that of partial agonists and yet BVT.13 makes no
direct hydrogen bond to H12 (Ostberg et al., 2004).
In this study, we sought to determine how ligands of
PPARg can afford graded transcriptional responses in
the absence of H12 stabilization. We extended our previ-
ous studies by coupling HDX analysis with X-ray crystallo-
graphic studies to profile a series of agonists that afford
graded transcriptional activation. Ligands included two
full agonists (>80% TA as compared to rosiglitazone),
three partial agonists (<50% TA), and a compound with
intermediate transactivation (between 50% and 80%
TA). Recent improvements in our HDX platform facilitated
rapid, robust, and quantitative assessment of amide HDX
for the entire receptor LBD (Chalmers et al., 2006). HDX
kinetics of H12 was altered only in the presence of full
agonists such as rosiglitazone. Analysis of partial agonists
and the intermediate agonist BVT.13 demonstrated that
the dynamics of H12 was unaltered by these ligands.
Thus, H12 cannot control activation of the receptor by
agonists with transactivation activation below 80% as
compared to rosiglitazone. In addition to differences in
H12 stabilization, the intermediate and partial agonists
demonstrated statistically significant protection to ex-
change in the b sheet region of the receptor. In order to
better understand the molecular details that underlie this
novel structural feature, we obtained six crystal structures
of PPARg bound to the ligands described above. The full
agonist afforded the expected hydrogen bond directly to
H12; however, the remaining ligands demonstrated inter-
actions with the b sheet, revealing a structural feature that
can be exploited by high-affinity intermediate and partial
agonists.
In summary, these data refute the hypothesis that the
dynamics of H12 is the only mediator of graded transcrip-
tional responses. We also demonstrate that other struc-
tural features such as the b sheet region of PPARg are
important in ligand-specific activation of the receptor,
and these regions likely represent novel interaction sites
for coactivators. These studies highlight the power of
combining crystallographic studies with comprehensive
HDX profiling, and the results presented provide novel
insight into the mechanism of ligand activation of nuclear
receptors.
RESULTS
Agonists Display a Wide Gradient
of Transcriptional Activation
We assembled a small collection of PPARg modulators,
most of which were previously described in the literature
(Figure 1A). These ligands demonstrated varying potency
in a FRET-based HTRF assay and afforded graded71, October 2007 ª2007 Elsevier Ltd All rights reserved 1259
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Mechanism of Ligand Activation of PPARgFigure 1. PPARg Ligands and Graded Transcriptional Responses
(A) Chemical structures of the ligands.
(B) Relative FRET for the indicated compounds in a HTRF-based assay.
(C) Cos-1 cells were transfected in triplicate with a PPARg expression vector and DR-1-luciferase reporter for 24 hr with the indicated compounds.
(D) Human 293T cells were transfected in triplicate with a PPARg expression vector and PPREX3-luciferase reporter for 24 hr with the indicated
compounds. Error bars represent the standard deviation around the mean value where n = 3.transcriptional responses in a cell-based luciferase re-
porter assay similar to that previously described with
a few modifications (Figures 1B–1D) (Berger et al., 2003).
Two of these compounds, MRL-24 and nTZDpa, are
high-affinity partial agonists that afforded low levels of
transactivation activation (Figures 1C and 1D), consistent
with previous reports (Acton et al., 2005; Berger et al.,1260 Structure 15, 1258–1271, October 2007 ª2007 Elsevier L2003). These compounds represent important chemical
probes because of their desired pharmacological profile
in animal models of type 2 diabetes such as the diet-
induced obese mouse or the leptin-receptor-impaired
db/db mouse models, where these compounds improve
insulin sensitization in the absence of weight gain, plasma
volume expansion, or increased heart weight (Acton et al.,td All rights reserved
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series, we synthesized SR145 and SR147, which dis-
played similarly modest transactivation profiles (Figures
1C and 1D). The partial agonist MRL-24 is a regioisomer
of the full agonist MRL-20, differing only by meta versus
ortho placement of the lactate group, providing amatched
set of ligands for structural comparison. Lastly, we exam-
ined the PPARg ligand BVT.13, which in previous crystal-
lographic studies (Ostberg et al., 2004) was shown to not
interact with H12. This ligand demonstrates intermediate
transcriptional efficacy (60% relative to rosiglitazone,
Figures 1C and 1D). As described below, the X-ray crystal
structure revealed that nTZDpa binds very similarly to
BVT.13, but they displayed divergent transactivation pro-
files, again providing a matched set of compounds for
structural comparison.
Structure Determination
PPARg LBD was crystallized alone and ligands were
soaked into apo crystals. The phase problem was solved
by molecular replacement and the resolution of six ligand
bound structures ranged from 2.05–2.40 A˚ (Table 1). The
structures revealed the canonical nuclear receptor tertiary
fold, comprised of three layers of a helices and a four
strand b sheet (Figure 2A). The PPARg LBD asymmetric
unit contained one dimer, with nearly identical monomers.
In each of the structures, H12 was distorted in one of the
monomers due to crystallographic contacts, consistent
with previously published PPARg structures (Cronet
et al., 2001; Ebdrup et al., 2003; Nolte et al., 1998; Ober-
field et al., 1999; Sauerberg et al., 2002). The overall struc-
ture of the PPARg LBD remained largely unchanged
among these six ligand-bound receptor complexes and
all structures showed a strong overall agreement with
rosiglitazone-bound PPARg, with rmsd values ranging
from 0.64–0.81 A˚ for superimposed alpha carbons
(Figure 2B).
Composite omit 2fo-fc difference maps for the observed
structures revealed clear and unambiguous density for all
of the ligands (Figures 3A–3F). Previously, the structure of
the intermediate agonist BVT.13 bound to PPARg LBD
and a coactivator peptide was reported (Ostberg et al.,
2004). The structure presented here (Figure 3F) was
obtained in absence of a coactivator peptide and was
solved at a resolution 0.5 A˚ higher than the one reported
previously. Our structure revealed water molecules in
the binding pocket that make contacts with the intermedi-
ate agonist. Also presented here is the structure of PPARg
bound to the partial agonist nTZDpa (Figure 3C), which oc-
cupies a similar location in the ligand binding pocket as
the intermediate agonist BVT.13. Two analogs of nTZDpa,
SR145 and SR147, are also reported (Figures 3D and 3E);
finally, structures of two regioisomers MRL-20 (full ago-
nist) and MRL-24 (partial agonist) are shown in Figures
3A and 3B.
Hydrogen/Deuterium Exchange of PPARg LBD
To understand the role of dynamics in mediating agonist
activity, we performed comprehensive differential HDXStructure 15, 1258–12experiments on the following ligand-receptor complexes:
PPARg LBD ± rosiglitazone, MRL-20, MRL-24, nTZDpa,
and BVT.13. HDX analysis of SR145 and SR147 was not
performed as these ligands demonstrated equivalent
transactivation activation as the precursor compound
nTZDpa. Each differential HDX experiment measured
exchange kinetics of 27 different regions of the receptor
LBD. For each of the 27 regions of the receptor, a compar-
ison was made between the exchange kinetics of the apo
receptor to that of ligand-bound receptor. The reduction in
HDX kinetics for each region of the receptor following
ligand interaction is detailed in Figure 4. Figure S1 (see
the Supplemental Data available with this article online)
shows the underlying %D versus Log time plots for every
peptide in the dataset. Improvements to our HDX platform
since our previous work on PPARg, such as the inclusion
of a 1 s on-exchange time point, allowed us to accurately
measure HDX of highly dynamic regions of the receptor.
More importantly, the implementation of parallel analysis
of an apo-receptor sample for each ligand complex, cou-
pled with a randomized order of analysis, eliminated sys-
tematic errors and improved our ability to observe subtle
changes in receptor dynamics.
As shown in Figure 5, the apo receptor demonstrated
a build-up of deuterium inH12 (residues 470–477) that sat-
urated by 30 s. The full agonists rosiglitazone andMRL-20
significantly reduced the rate of amide exchange kinetics
for H12. However, no statistically significant stabilization
of H12 was observed for either the partial agonist MRL-
24 and nTZDpa or the intermediate agonist BVT.13. The
b sheet region (amino acids 341–351) is another area of re-
ceptor that demonstrates differential HDX following ligand
binding (Figure 4 and Figure 5). Full agonists showedmod-
erate stabilization of this region. In contrast, MRL-24,
nTZDpa, and BVT.13 induced robust protection from ex-
change in this region. As discussed below, the crystal
structures identified a hydrogen bonding network be-
tween these ligands and the b sheet that was not found
with the full agonists. Figure 6 illustrates how HDX kinetics
in H12, b sheet, and H3 correlate with transactivation effi-
cacy. The activity of BVT.13 is completely independent of
H12, and there is an apparent compensation of b sheet
stabilization as H12 stabilization is decreased (Figure 6B).
The putative structural features governing this phenome-
non are described below.
Intermediate and Partial Agonism Does
Not Correlate with Stabilization of H12
The full agonists rosiglitazone and MRL-20, when bound
to receptor, induced a statistically significant reduction
in the rate of amide exchange kinetics for H12. In addition,
the degree of stabilization of H12 was consistent with the
degree of transactivation for these full agonists. Full ago-
nist MRL-20 shows 20% less transactivation compared
to rosiglitazone while also showing a lower degree of
H12 stabilization compared to rosiglitazone (Figure 6A).
As described above, no statistically significant stabiliza-
tion of H12 was observed for either partial agonist MRL-
24 or nTZDpa. More importantly, stabilization of H1271, October 2007 ª2007 Elsevier Ltd All rights reserved 1261
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BVT.13 MRL-24 SR147 MRL-20 nTZDpa SR145
Data Collection
Beamline APS SER-CAT APS SER-CAT APS SER-CAT SSRL BL1-11 SSRL BL1-11 SSRL BL-1-11
Wavelength (A˚) 0.9764 0.9764 0.9764 0.9537 0.9537 0.9537
Space group C2 C2 C2 C2 C2 C2
Unit cell parameters (A˚)
a 92.3 91.4 90.8 89.2 89.7 90.1
b 62.0 61.5 62.3 63.9 62.2 62.4
c 118.1 117.9 118.1 119.2 118.0 117.9
Unique angle () b 102.3 102.4 101.1 103.4 101.0 101.0
Resolution (A˚) 15–2.4 15–2.3 15–2.4 15–2.2 15–2.05 15–2.2
Unique reflections 20,711 24,664 21,496 31,004 34,179 35,178
Average redundancy 6.3 (4.0) 6.3 (4.4) 6.3 (3.3) 6.8 (4.3) 6.9 (4.4) 7.1 (6.7)
Completeness (%)1 91.4 (59.1) 91.7 (63.5) 91.3 (56.8) 99.2 (99.2) 99.3 (95.3) 99.4 (99.6)
Rmerge
2 0.056 (0.173) 0.049 (0.119) 0.068 (0.196) 0.073 (0.42) 0.055 (0.34) 0.066 (0.42)
I/s 26.8 (7.6) 25.4 (10.4) 24.6 (4.8) 23.1 (2.9) 33.4 (3.4) 30.2 (4.7)
Refinement
Resolution (A˚) 2.4 2.3 2.4 2.2 2.05 2.2
Rfree
3/Rwork
4 26.4/20.6 24.7/20.6 28.4/26.9 23.0/18.0 24.5/19.7 23.5/19.6
Average B factor (A˚2)
Protein 39.58 43.81 90.21 21.99 23.86 22.59
Ligand 68.33 63.42 70.17 33.19 33.796 34.23
Water 66.56 50.78 59.15 37.15 44.29 36.42
Number of Atoms
Protein 4107 4048 3887 4060 4114 4165
Ligand 27 76 58 76 56 54
Water 151 100 125 244 264 156
Rmsd
Bonds (A˚) 0.012 0.011 0.009 0.011 0.010 0.010
Angles () 1.276 1.303 1.616 1.39 1.354 1.171
Ramachandran Analysis5 (%)
Core + Allowed 99.2 99.8 98.2 100 99.8 99.3
Generously allowed 0.9 0.2 1.8 0 0.2 0.6
Disallowed 0 0 0 0 0 0
1 Values in parentheses correspond to the last shell.
2 Rmerge = S jI  < I > j / S I.
3 Rfree = S jFo  Fcj / S jFoj, for all data.
4 Rwork = S jFo  Fcj / S jFoj for all data excluding data to used to calculate Rfree.
5 Calculated using PROCHECK.was not observed for the intermediate agonist BVT.13
(Figure 6A). Contrary to previous models, these data
suggest that weak activators of PPARg (<80%) are not
regulated through changes in stabilization or dynamics
of H12. The b sheet region (amino acids 341–351) un-1262 Structure 15, 1258–1271, October 2007 ª2007 Elsevierdergoes differential HDX following ligand binding (Fig-
ure 5), suggesting a possible role of this region of the
LBD in ligand-mediated activation of the receptor. Full
agonists afforded moderate stabilization, whereas MRL-
24, nTZDpa, and BVT.13 induced robust protection fromLtd All rights reserved
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Mechanism of Ligand Activation of PPARgFigure 2. Overall Structure Comparison
of PPARg Bound to Agonists and Partial
Agonists
(A) Ribbon diagram of PPARg (green) bound to
MRL-20 (yellow sticks).
(B) The figure shows a Ca trace of superim-
posed PPARg monomers bound to rosiglita-
zone, MRL-20, MRL-24, nTZDpa, SR145,
SR147, and BVT.13 Ligand-bound proteins
colored as: rosiglitazone (PDB code: 2PRG)
(Nolte et al., 1998) (purple), MRL-20 (forest
green), MRL-24 (pink), nTZDpa (green),
SR145 (cyan), SR147 (orange), and BVT.13
(yellow). Ligands are not shown.exchange in this region. As discussed below, the crystal
structures identified a common hydrogen bond network
between these ligands, and the b sheet that was not found
with the full agonists. Figure 6C suggests a compensatory
mechanism of b sheet interaction to compensate for lack
of H12 stabilization.
Among the six crystal structures, only the full agonist
MRL-20 demonstrated the hydrogen bonding pattern to
H12 that is observed in other full agonist crystal structures
(Figures 7A and 7B), a feature consistent with the HDX
data showing significant stabilization of H12. The partial
agonists and intermediate agonist BVT.13 displayed no
stabilization of H12, and no physical interaction with H12
was observed in the crystal structures as well (data not
shown). With MRL-20, three hydrogen bonds extended
from the acid of the lactate group to residues His323
(H6), His449 (H11), and Tyr473 (H12), as shown in Fig-
ure 7B. Hydrogen bonding with these residues has been
seen in many agonist structures (Cronet et al., 2001;
Ebdrup et al., 2003; Mahindroo et al., 2005; Nolte et al.,
1998; Sauerberg et al., 2002) and is imperative for full
activity of these compounds by direct stabilization of H12.
Residue Ser289 formed a hydrogen bond with the ether
oxygen of MRL-20 and was within hydrogen bonding dis-
tance of the acidic oxygen of the lactate group as well
(Figure 7B), suggesting that this interaction may also indi-
rectly contribute to the lactate interaction with H12.
Ligands That Do Not Robustly Stabilize H12
Stabilize the b sheet Region of the LBD
MRL-20 and MRL-24 showed an almost 180 rotation
from each other within the ligand-binding pocket (Fig-
ure 7C), allowing for different atomic contacts that are
reflected in unique changes to the dynamics of the LBD
as determined by HDX analysis. In the partial agonist
MRL-24 structure, the lactate group was found nestled
against the b sheet making hydrogen bonds as well as
hydrophobic and van der Waal contacts (Figure 7D). The
acid portion of the lactate was positioned such that both
oxygens are in hydrogen-bonding distance to contact
the main chain amide nitrogen of Ser342 as well as a wa-
ter-mediated contact to Glu343. The lactate group was
positioned such that it was in contact distance with
Ile341, Leu340, and Met348. This altered positioning ofStructure 15, 1258–1the lactate group, from ortho to meta, induced a flip in
ligand positioning allowing interaction of the partial ago-
nist MRL-24 with the b sheet. The observed binding
mode of MRL-24 was consistent with the HDX data, which
showed no statistically significant stabilization of H12 (Fig-
ure 5) but robust increased stabilization of the b sheet.
Both BVT.13 and nTZDpa also demonstrated stabiliza-
tion of the b sheet relative to the full agonists as deter-
minedHDX. The indole of nTZDpamakes several contacts
with the b sheet, mostly hydrophobic in nature, especially
with Ile341 as shown in Figure 7E. The 2-carboxy group of
the indole formed one direct hydrogen bond with Ser342
(2.76 A˚) as well as a water-mediated hydrogen bond
with Glu343. The position of the carboxylate of nTZDpa
was rotated in perspective to that of BVT.13, only allowing
one of the carboxylate oxygens to contact the b sheet
directly.
In contrast to nTZDpa, the hydrogen bond network from
BVT.13 to the b sheet was more extensive, differences
thatwere reflected in the large protection inHDX (Figure 5).
The carboxylate of BVT.13 had three contacts in hydrogen
bonding distance to Ser342: two directly from each car-
boxylate oxygen (3.07 A˚ and 3.35 A˚) as well as a water-
mediated bond (Figure 7F). These changes in atomic
contacts were reflected in the HDX kinetics for residues
341–351, with a 29% reduction in rate for nTZDpa as com-
pared to a 37%reduction forBVT.13, differences thatwere
statistically significant (p < 0.001). In addition, the benzoyl
group of BVT.13 contained two chlorines, whereas, the
benzyl group in nTZDpa contained only one. One of the
chlorines of BVT.13 was positioned to make a tighter
van der Waal surface with the b sheet (residue Leu340)
as seen in Figure 7F. This space filling was not available
in the nTZDpa structure to contact the b sheet, as the
benzyl group only consists of one chlorine which was
positioned further away at the H3 and H5 interface.
Thus, these data demonstrate that HDX can discriminate
subtle atomic differences in the interaction of ligands with
receptor.
The combination of HDX and crystallography has iden-
tified the hydrogen bonding between ligand and b sheet
as an epitope for high-affinity interaction with partial
agonists. It is notable that previously described partial
agonist crystal structures including that of GW0072271, October 2007 ª2007 Elsevier Ltd All rights reserved 1263
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Mechanism of Ligand Activation of PPARgFigure 3. Stereo View of Electron Density
Electron density is shown from composite omit 2Fo-Fc maps (con-
toured at 1s) of ligands, with the exception of SR147, which was cal-
culated as an omit map with ligand model deleted.
(A) MRL-20.1264 Structure 15, 1258–1271, October 2007 ª2007 Elsevier Ltdemonstrate a hydrogen bond between ligand and the
b sheet, highlighting the importance of this structural fea-
ture (Oberfield et al., 1999). Thus, targeting the b sheet for
high-affinity interaction with the receptor, rather than
H12, defines a broadly used binding epitope for partial
agonists.
H3 Is Differentially Stabilized as a Function
of Binding Mode
Among the full and partial agonists tested, ligands were
broadly grouped into those that occupy the portion of
the LBD spanning fromH11 and H12 beyond H3 (rosiglita-
zone, MRL-20, and MRL-24) and those that occupy the
region between H3 and the b sheet only (nTZDpa and
BVT.13). The previously described GW0072 ligand would
fall into the second class. Among both classes of com-
pounds, the partial agonists showed differential stabiliza-
tion of H3 when compared to the full agonists. With the
first class of compounds, stronger transactivation was
achieved with a corresponding decrease in stabilization
of H3 (Figure 6D); this can perhaps be explained by the
ability of the compounds in this area to achieve increases
in transactivation by directly stabilizing H12. In contrast,
compounds unable to directly contact H12 showed in-
creased stabilization of H3 in proportion with transactiva-
tion efficacy (Figure 6E).
The HDX studies revealed increased stabilization of H3
with the partial agonist MRL-24 (46%) relative to MRL-20
(34%), differences that are significant (p value < 0.0001)
and consistent with the differences in ligand-binding
modes. MRL-20 was positioned closer to H3 than MRL-
24 and was in contact distance with Ile281, Gly284,
Cys285, Arg288, and Ala292 (Figure 8A). Due to its size
and proximity, the ring bearing the lactate group of
MRL-24 formed closer and more numerous hydrophobic
contacts and van der Waals contacts with residues
Cys285, Gly284, and Ile281. Although the trifluorome-
thoxy group of MRL-20 inserted close to H3 in the same
region, it did not extend across as large an area or as
closely as MRL-24, possibly due to the dispersive nature
of the fluorines. In addition, the Arg288 side chain was
pulled closer to the MRL-24 ligand than the MRL-20 li-
gand, making two hydrogen bonds with MRL-24. Neither
full agonist ligand MRL-20 nor rosiglitazone made hydro-
gen-bonding patterns with Arg288. Thus, the differences
in HDX kinetics for H3 reflected subtle structural differ-
ences in ligand interaction with the receptor, highlighting
the relative strengths of these approaches to identify crit-
ical regions of stabilization and explain the molecular de-
tails, respectively.
Differences in HDX kinetics between BVT.13 and
nTZDpa can be explained by BVT.13 contacting a larger
(B) MRL-24.
(C) nTZDpa.
(D) SR145.
(E) SR147.
(F) BVT.13.d All rights reserved
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Mechanism of Ligand Activation of PPARgFigure 4. Changes in H/D Exchange Rates for Regions of PPARg LBD upon Binding of Ligands
Secondary structure regions as described in Uppenberg et al., 1998.surface area of H3 than nTZDpa, making different hydro-
gen bonds with H3, as well as making more hydrophobic
contacts overall. Both structures made several contacts
with Arg288 found on H3. In the nTZDpa structure,
Arg288, as with other full and partial agonists, extended
across a large portion of the ligand, clamping it in place
between H3 and the b sheet. In contrast, BVT.13 was po-
sitioned closer to Arg288 than nTZDpa, allowing for more
hydrophobic and van der Waals contacts (Figures 7E and
7F). There were also differences between nTZDpa and
BVT.13 in the manner of interaction with a large portion
of H3. The thiophenyl group of nTZDpa extended parallel
along H3 and made hydrophobic contacts with Ile247,
Leu255, Glu259, Met348, and Ile281. On the other
hand, BVT.13 extended deeper into the region between
the lower portion of H3 and H20 (Figure 8B). The pyrimi-
dine ring of BVT.13 afforded a hydrogen bond contact
with His266 (3.42 A˚), but this interaction was absent in
the nTZDpa structure. There was also a stacking interac-
tion with the pyrimidine ring and Phe264 that was not
observed in the nTZDpa structure. These structural
observations suggested that the increased protection
in H/D exchange in this region directly reflected ligand-
mediated stabilization of the secondary structural ele-
ments.Structure 15, 1258–1DISCUSSION
Graded transcriptional responses have been suggested to
derive from differential modulation of H12 (Kallenberger
et al., 2003; Nagy and Schwabe, 2004; Nettles and
Greene, 2005). In the work presented here, we employed
quantitative amide HDX to demonstrate that only full ago-
nists stabilize H12. Ligands that afford weak or intermedi-
ate levels of transactivation (<80% TA) are not associated
with statistically significant stabilization of H12. We also
show that stabilization of H3 and H11 are not sufficient
to stabilize H12, suggesting that coactivator recruitment
by partial agonists derives from a distinct mechanism
(Burgermeister et al., 2006; Fujimura et al., 2006).
What is the mechanism of high-affinity ligands affording
varying magnitudes of agonism of PPARg? It is clear that
partial agonists stabilize the LBD in a distinct manner in
comparison to full agonists. Previous studies using NMR
have shown that full agonists stabilize large portions of
the LBD (Berger et al., 2003; Johnson et al., 2000; Klein
et al., 2005). Fluorescence anisotropy was employed to
demonstrate full-agonist stabilization of H12 (Kallenberger
et al., 2003). Our studies showed that compounds that
do not stabilize H12 differentially stabilize other regions
of the LBD, and the magnitude of transactivation varied271, October 2007 ª2007 Elsevier Ltd All rights reserved 1265
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Mechanism of Ligand Activation of PPARgFigure 5. Differential H/D Exchange Data Plotted as a Percentage Incorporation of Deuterium versus Time in Seconds
HDX data for the apo PPARg LBD is represented by the black line. The gray line represents the HDX data for the ligand-bound PPARg LBD. The
shaded region between the lines represents the percentage reduction in HDX values that make up the data in Figure 4. All ligands induced a reduction
of exchange rate for H3 (residues 279–287) upon binding. MRL-20 and nTZDpa reduced exchange rate to a lesser degree than MRL-24 and BVT.13.
The b sheet region (341–351) showed a gradient in reduction of exchange rate upon binding MRL-20, MRL-24, nTZDpa, and BVT.13. Only the full
agonists rosiglitazone and MRL-20 stabilized H12 (residues 470–477) to a statistically significant extent providing direct evidence that stabilization
of H12 is not required for activation of PPARg. Statistical summary from a 2-way ANOVA between apo and ligand bound data: ***, p < 0.001; **,
p < 0.001–0.01; *, p < 0.01–0.5; ns, not significant. The value in parenthesis represents the charge state of the peptide ion. Error bars represent
the standard deviation around the mean value where n = 4.depending on the overall stabilization pattern induced
by the ligand. For example, BVT.13 preferentially stabi-
lized the b sheet and H3 to a larger degree than nTZDpa,
while the partial agonist MRL-24 preferentially stabilized
the b sheet and H3 to a larger degree than MRL-20. Since
there was no change in conformation upon binding these
various ligands, full agonists may function by directly sta-
bilizing the AF-2 coactivator binding site, while partial ag-
onists only stabilize regions away fromH12, leaving H12 in
a highly dynamic state. This differential stabilization may
also transmit to regions of the receptor away from AF-2,
such as the b sheet, suggesting a distinct coactivator-
binding surface, consistent with the findings that regions
outside the LxxLL motifs contribute to receptor binding
(Klein et al., 2005; Puigserver et al., 1998). Another possi-
bility is that non-AF-2 coactivator recruitment could be fa-
cilitated by conformational changes induced in the dimer
partner, RXR, which could not be tested here. However,
further improvements in our HDX platform are underway
to facilitate analysis of dynamics of the PPAR/RXR heter-
odimer as a function of ligand. The results presented here
highlight that understanding allosteric communication be-
tween ligand- and coactivator-binding sites requires anal-
ysis of both high-resolution structure and conformational
dynamics.1266 Structure 15, 1258–1271, October 2007 ª2007 Elsevier LtdIn summary, we have shown through X-ray crystallogra-
phy and HDX that subtle differences among PPARg
ligands can elicit statistically significant differences in
receptor dynamics, binding mode, and degree of agonist
activity. Here we demonstrate that agonists with less than
80% transactivation efficacy as compared to rosiglitazone
do not stabilize H12, suggesting that a non-H12-depen-
dent mechanism exists to control coactivator recruitment
to the receptor in response to this class of ligand. Among
the ligands lacking full agonist activity, all demonstrated
protection from exchange in the b sheet region, allowing
high-affinity ligand interaction with PPARg. An analysis
of paired ligands further demonstrates that subtle atomic
differences in ligand-binding modes were reflected in the
HDX analysis, highlighting the strength of this approach to
rapidly and sensitively probe ligand-binding mode and
structural dynamics.
EXPERIMENTAL PROCEDURES
Cell-Based Transactivation Assay
COS-1 cells were seeded at 12 3 103 cells/well in 96-well cell culture
plates in high-glucose Dulbecco’s modified Eagle’s medium contain-
ing 10% fetal bovine serum (Hyclone), nonessential amino acids, 100
units/ml penicillin G, and 100 mg/ml streptomycin sulfate at 37C inAll rights reserved
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Mechanism of Ligand Activation of PPARgFigure 6. Comparison of HDX Data
among Different Ligands within the Helix
12, Helix 3, and b Sheet Regions
(A) Cell-based transactivation data.
(B) Helix 12 is only stabilized by full agonists.
Partial and intermediate agonists show no sta-
tistically significant stabilization pattern com-
pared to the apo structure.
(C) Partial agonists preferentially stabilize the
b sheet.
(D) Class I ligands with weaker transaction pro-
files preferentially stabilize helix 3.
(E) Class II ligandswith stronger transactivation
profiles preferentially stabilize helix 3.
Error bars represent the standard deviation
around the mean value where n = 3 (A) and
n = 4 (B–E).a humidified atmosphere of 5% CO2. After 24 h, transfections were
performed with LipofectAMINE (Life Technologies Inc.) according to
the instructions of the manufacturer. Briefly, transfection mixes for
each well contained 0.25 mg of each expression vector containing
full-length PPARg, peroxisome proliferator-activated receptor re-
sponse element (PPRE), DR1-Luciferase reporter, and LipofectAMINE
reagent at a ratio of 1:5 (mg of DNA/ml of reagent). Cells were incu-
bated in the transfection mixture for 6 hr at 37C in a humidified atmo-
sphere of 5% CO2. The cells were then washed with phosphate-buff-
ered saline and incubated for 24 hr in fresh high-glucose Dulbecco’s
modified Eagle’s medium containing 5% fetal calf serum, nonessential
amino acids, 100 units/ml penicillin G, and 100 mg/ml streptomycin
sulfate ± increasing concentrations of test compound. Since the com-
pounds were solubilized in DMSO, control cells were incubated with
equivalent concentrations of DMSO; final DMSO concentrations
were equal to 0.1%, a concentration that was shown not to affect
transactivation activity. Cells were harvested and lysates were pro-
duced using reporter lysis buffer (Promega) according to the manufac-
turer’s instructions. Luciferase activity in cell extracts was determined
using Luciferase assay buffer (Promega) in a luminometer (Analyst GT,
Molecular Devices).
Biochemical Coactivator Recruitment Assay Using FRET
Sample wells contain a mixture of 1 nM GST-PPARgLBD, 2 nM anti-
GST-(Eu)K, 10 nM FLAG-SRC1, 20 nM anti-FLAGXL665, and 2 mlStructure 15, 1258–1test compound in buffer containing 100 mM phosphate, 125 mM KF,
0.5% (wt/vol) 3-[(3-cholamidopropyl) dimethyl-ammonio]-1-propane-
sulfonate (CHAPS), 0.1% BSA, in a volume of 100 ml (96-well format).
These reactions were routinely incubated overnight at 4C. The mix-
tures are irradiated at 330 nm (corresponding to the europium absorp-
tion band) and the fluorescence emission intensity of the XL665 accep-
tor at 620 nm and 665 nm are simultaneously recorded with 50 ms time
delay and an integration time of 0.2 s. Data were typically expressed as
the ratio, multiplied by a factor of 104, of the fluorescence intensity at
665 nm to that at 620 nm. Agonist dose-response was generated by
titrating increasing concentrations of compound and measuring
FRET after each addition.
PPARg Protein Expression and Purification
DNA encoding the LBD of PPARg (encoding amino acids 205–477)
was amplified by PCR and cloned into the expression vector
pMCSG19 (Stols et al., 2002). This expression construct produced
an N-terminal MBP (maltose binding protein) fused to PPARg with
a TEV (tobacco etch virus) protease recognition site for removal of
MBP. The plasmid pMCSG13-PPARg-LBD was transformed into
E. coliRosetta cells (Novagen). Cells were grown at 37C in LBmedium
containing 30 mg/ml chloramphenicol and 50 mg/ml ampicillin. Expres-
sion of PPARgwas induced by the addition of isopropyl b-D-thiogalac-
toside to a final concentration of 0.5 mM and grown an additional 16–
18 hr. Cells were resuspended in 20 mM Tris-HCl (pH 8.0), 0.5 M NaCl,271, October 2007 ª2007 Elsevier Ltd All rights reserved 1267
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Mechanism of Ligand Activation of PPARgFigure 7. Structural Details of Hydrogen-
Bonding Networks of Full and Partial
Agonists
PPARg (green), rosiglitazone (blue), MRL-20
(white), MRL-24 (yellow), nTZDpa (yellow),
and BVT.13 (white).
(A) Hydrogen-bonding network of the rosiglita-
zone (PDB code: 2PRG) TZD head group to
conserved PPARg residues (Nolte et al., 1998).
(B) Hydrogen-bonding network of the MRL-20
lactate group to conserved PPARg residues.
(C) MRL-20 and MRL-24 represented as stick
figures as they lie in the binding pocket gener-
ated by superimposition of the respective pro-
tein molecules.
(D) The lactate group of MRL-24 contacts the
b sheet making several hydrogen bonds.
(E) The hydrogen bonding network of nTZDpa
contacts the b sheet and Arg288 adopts two
defined conformations.
(F) The hydrogen bonding network of BVT.13
contacts the b sheet.10mM imidazole, 10% glycerol, and 5 mM BME (b-mercaptoethanol).
20 mM Tris (pH 8.0), 5 mM BME, and 10% glycerol were included in all
buffers following lysis. Cells were lysed by sonication and pelleted by
centrifugation. The supernatant was applied to a 5 ml His-Trap FF
crude column (GE Healthcare). PPARg was eluted with an imidazole
gradient (0.01–0.5 M). Fractions containing PPARg were pooled and
dialyzed to 2 liters dialysis buffer containing 1 mM imidazole and
20 mM NaCl. In addition, the MBP fusion was removed proteolytically
using TEV protease at a weight ratio of 20:1 (fusion protein:TEV prote-
ase) during dialysis. To remove TEV protease, MBP, and nonproteo-
lyzed MBP-PPARg, the dialyzed protein solution was passed over
a 5 ml His-Trap FF crude column (GE Healthcare) again and the
flow-through was collected. PPARg was then applied to a Mono Q
HR 10/10 column (GE Healthcare) and eluted with a linear NaCl gradi-
ent (0.01–0.5 M). PPARg was dialyzed extensively to 20 mM Tris-HCl
(pH 8.0), 10%glycerol, 150mMNaCl, and 1mMDTT. PPARgwas con-
centrated to 10 mg/ml using a 10,000 molecular weight cut off Amicon
Ultra 15 centrifugal concentrator (Millapore) and flash frozen prior to
storage at 130C. Finally, the purity of the protein was confirmedby ESI MS. A single component corresponding to the mass of the
PPARg LBD was identified (data not shown).
Crystallization and Data Collection
Crystals of apo-PPARg were grown by vapor diffusion in hanging
drops at 20C. PPARg (1 ml) was mixed with 1 ml well solution con-
taining 1.3 M sodium citrate (pH 5.6) and 20 mM Tris-HCL (pH 8.0).
Cubic-shaped crystals grew within 3–7 days. PPARg ligands were
soaked into PPARg apo-crystals by adding 0.5 ml of compound at
a concentration of 5 mM suspended in well solution containing 5%
DMSO (not all compounds were soluble at this concentration; solu-
tion containing precipitated compound was added to crystal drops
when necessary) directly to the crystal drop. Crystals were soaked
from 3 days to 3 weeks depending on the compound. All crystals
were transferred to a cryoprotectant comprised of well solution con-
taining 20% glycerol and covered with paraffin oil, and flash frozen.
The measurements were carried out using 10 s exposures at the syn-
chrotron and 360 (using 1 increments) of crystal data were col-
lected. This amounted to approximately 2–4 hr of data collectionFigure 8. Structural Details of H3 and H20
Ligand Packing with PPARg Shown in
Green
(A) Partial agonist MRL-24 (yellow) lies close to
H3 and makes more contacts to H3 than its full
agonist counterpart MRL-20.
(B) Superimposition of the nTZDpa ligand (yel-
low) onto the BVT.13 (white) structure high-
lighting contacts of the lower portion of H3,
H20 and the adjoining loop.
1268 Structure 15, 1258–1271, October 2007 ª2007 Elsevier Ltd All rights reserved
Structure
Mechanism of Ligand Activation of PPARgtime. There was no observed radiation decay of the crystals over the
course of data collection as monitored by comparing the intensities
and the resolution of reflections of the initial frames to the final
frames.
Structure Determination and Refinement
Data was collected at the APS SER-CAT and SSRL BL1-11 beamlines
and processed with HKL2000 (Otwinowski and Minor, 1997). All struc-
tures were solved by molecular replacement using MOLREP in CCP4
(CCP4, 1994) and the previously published PPARg structure (PDB
code: 1KNU) (Sauerberg et al., 2002) as the search model. To avoid
biasing our maps, all water molecules and ligands were excluded. Re-
finement of all structures was carried out in CCP4 (CCP4, 1994) and
model building was carried out in Coot (Emsley and Cowtan, 2004).
Difference Fourier maps gave strong and clear density to build all
ligands. Several rounds of manual rebuilding in Coot followed by re-
finement in CCP4 were carried out. TLS refinement was carried out
with most of the structures.
HDX Analysis
Solution-phase amide HDX was performed with a fully automated sys-
tem that is described in detail elsewhere (Chalmers et al., 2006).
Briefly, 4 ml of a 10 mM protein solution (20 mM Tris-CL [pH 7.9], con-
taining 20%glycerol, 100mMKCl, 0.2MEDTA, 1mMDTT) was diluted
to 20 ml with D2O dilution buffer (20 mM Tris-CL [pH 7.9], containing
100 mM KCl, 1 mM DTT) and incubated at 25C for the following pe-
riods of time: 1, 30, 60, 900, and 3600 s. Each differential HDX
experiment required approximately 2 nmol of total protein. Following
on-exchange, unwanted forward or back exchange was minimized
and the protein was denatured by dilution to 50 ml with 0.1% TFA in
2M urea (held at 1C). Sample was then passed across an immobilized
pepsin column (prepared in house) at 200 ml min-1 (0.1%TFA, 1C) and
the resulting peptides were trapped onto a C18 trap cartridge (Microm
Bioresources). Peptides were then gradient eluted (4%CH3CN to 40%
CH3CN, 0.3% formic acid over 15 min, 2
C) across a 2.1 mm3 50 mm
C18 HPLC column (Hypersil Gold, Thermo Electron) and electro-
sprayed directly into a linear ion trapmass spectrometer (LTQ, Thermo
Electron). Data were processed with in-house software (Pascal et al.,
2007) and Microsoft Excel and visualized with pyMOL (DeLano Scien-
tific). To measure the difference in exchange rates, we calculated the
average percentage deuterium uptake for 27 regions of the apo PPARg
LBD following 1, 30, 60, 900, and 3600 s of on-exchange. From this
value, we subtract the average percent deuterium uptake measured
for the PPARg LBD + ligand complex.
Chemical Synthesis of Ligands
The PPARg agonists MRL-20, MRL-24, nTZDpa, SR147, and SR145
were synthesized following previously described chemical strategies
(Acton et al., 2005; Berger et al., 2003) and were isolated to >98%
purity. Rosiglitazone was purchased from ChemPacific Corp.
Supplemental Data
Supplemental data including one supplemental figure are available
online at http://www.structure.org/cgi/content/full/15/10/1258/DC1/.
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